logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure INF-9. Prevalence of markers of HBV infection among injecting drug users: studies with national and sub-national coverage

Part (i) Percentage ever infected (positive for aHBc), 2010–11

 
 
CountryyearNationalSub-national
Related links:
Malta20111.2
Turkey20104
Estonia20105
Slovenia20118.1
Austria201110.310.433.347.80
United Kingdom201115.910.1
Slovakia201121.5
Sweden201023.4
Germany 201116.333
Greece 201132.321.61440.329.747.222.815.820.216.213.337.810.217.222.6
Netherlands201131.6
Norway201133.1
Italy 201033.953.18.521.724.811.129.146.650.728.822.119.56739.147.638.331.642.433.4
Belgium201155.116.7
Portugal2010/201181.524.0
Latvia201165.4
Poland
Lithuania
Bulgaria
Cyprus
Czech Republic
Finland
France
Hungary
Ireland
Luxembourg
Croatia
Romania
Spain
Denmark
https://www.emcdda.europa.eu/stats13/inffig9a: Figure INF-09 part (i).
For primary sources, study details and data before 2010, see Table INF-115 and Table INF-0.
See also 'General notes for interpreting data' on the Explanatory notes and help page

Notes:

Dark squares are samples with national coverage; blue triangle are samples with sub-national (including local or regional) coverage.

Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.

Countries are presented by order of increasing prevalence, based on the average of national data or, if not available, of subnational data.

* Italy provided a national estimate for 2010 only, even though regional data for 2011 were provided for many regions, but not for all (i.e. Liguria and Lombardia). So regional data for 2010 and not for 2011 are presented here as well for comparability reasons

Sources:

<a/ href="https://www.emcdda.europa.eu/about/partners/reitox-network">Reitox Network<a/>

Country Malta Turkey Slovenia Austria United Kingdom Slovakia Sweden Germany  Greece  Netherlands Norway Italy  Belgium Portugal Latvia
National 1.2 4 8.1 10.3     23.4   32.3     33.9   81.5  
National                 21.6         24.0  
                               
Subnational       10.4 15.9 21.5   16.3 14 31.6 33.1 53.1 55.1   65.4
 Subnational       33.3 10.1     33 40.3     8.5 16.7    
 Subnational       47.8         29.7     21.7      
 Subnational       0         47.2     24.8      
 Subnational                 22.8     11.1      
 Subnational                 15.8     29.1      
 Subnational                 20.2     46.6      
 Subnational                 16.2     50.7      
 Subnational                 13.3     28.8      
 Subnational                 37.8     22.1      
 Subnational                 10.2     19.5      
 Subnational                 17.2     67      
 Subnational                 22.6     39.1      
 Subnational                       47.6      
 Subnational                       38.3      
 Subnational                       31.6      
 Subnational                       42.4      
 Subnational                       33.4      

inffig9a

 

Page last updated: Monday, 23 November 2015